Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Beyond The REMS: Clozapine Adcomm Shows Why In-Program Assessments Are Not Always Enough
Dec 04 2024
•
By
Sue Sutter
Schizophrenics are suffering because of the FDA's "myopic" focus on absolute neutrophil counts with clozapine, patient advocates said.
(Shutterstock)
More from US Advisory Committees
More from Product Reviews